Ero sivun ”Rituksimabi” versioiden välillä

Wikipediasta
Siirry navigaatioon Siirry hakuun
Selaa historiaa interaktiivisesti
[katsottu versio][katsottu versio]
← Vanhempi muutosUudempi muutos →
Poistettu sisältö Lisätty sisältö
VisuaalinenWikiteksti
Rivi 5: Rivi 5:
Rituksimabin kehitti [[Biogen Idec|IDEC Pharmaceuticals]] tuotenimellä '''IDEC-C2B8'''.<ref>[http://www.sandiegometro.com/1999/apr/biotech.html "Why San Diego Has Biotech"], Fikes, Bradley J. ''San Diego Metropolitan,'' April 1999. Accessed June 20, 2008.</ref>
Rituksimabin kehitti [[Biogen Idec|IDEC Pharmaceuticals]] tuotenimellä '''IDEC-C2B8'''.<ref>[http://www.sandiegometro.com/1999/apr/biotech.html "Why San Diego Has Biotech"], Fikes, Bradley J. ''San Diego Metropolitan,'' April 1999. Accessed June 20, 2008.</ref>


Perustuen [[Kliininen tutkimus| kliinisiin tutkimuksiin]],<ref>{{cite journal |author=Maloney DG, Grillo-López AJ, White CA, ''et al.'' |title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma |journal=Blood |volume=90 |issue=6 |pages=2188–95 |year=1997 |month=September |pmid=9310469 |doi= |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469}}</ref> rituksimabi sai hyväksynnän USA:n [[FDA]]:lta vuonna 1997.<ref>{{cite journal |author=Scott SD |title=Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma |journal=Cancer Pract |volume=6 |issue=3 |pages=195–7 |year=1998 |pmid=9652253 |doi= 10.1046/j.1523-5394.1998.006003195.x|url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1065-4704&date=1998&volume=6&issue=3&spage=195}}</ref> Rituximab, in combination with [[CHOP]] chemotherapy, is superior to CHOP alone in the treatment of [[diffuse large B-cell lymphoma]] and many other B-cell lymphomas.<ref>''Harrison's Principles of Internal Medicine'', Longo et al. ''McGraw Hill Medical'' 2011 page 931</ref> In 2010 it was approved by the [[European Commission]] for maintenance treatment after initial treatment of [[follicular lymphoma]].<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/ |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref>
Perustuen [[Kliininen tutkimus| kliinisiin tutkimuksiin]],<ref>{{cite journal |author=Maloney DG, Grillo-López AJ, White CA, ''et al.'' |title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma |journal=Blood |volume=90 |issue=6 |pages=2188–95 |year=1997 |month=September |pmid=9310469 |doi= |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=9310469}}</ref> rituksimabi sai hyväksynnän USA:n [[FDA]]:lta vuonna 1997.<ref>{{cite journal |author=Scott SD |title=Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma |journal=Cancer Pract |volume=6 |issue=3 |pages=195–7 |year=1998 |pmid=9652253 |doi= 10.1046/j.1523-5394.1998.006003195.x|url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1065-4704&date=1998&volume=6&issue=3&spage=195}}</ref> Rituksimabia pidetään hyvänä lääkkeenä muiden kanssa hoidettaessa mm. monia B-solu lymfoomia.<ref>''Harrison's Principles of Internal Medicine'', Longo et al. ''McGraw Hill Medical'' 2011 page 931</ref> In 2010 it was approved by the [[European Commission]] for maintenance treatment after initial treatment of [[follicular lymphoma]].<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/roche-gets-ec-nod-for-follicular-lymphoma-maintenance-therapy/81244149/ |title=Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy |date=October 29, 2010 }}</ref>


Rituximab is currently co-marketed by [[Biogen Idec]] and [[Genentech]] in the U.S., by [[Hoffmann–La Roche]] in Canada and the [[European Union]], and by [[Chugai Pharmaceuticals]] and Zenyaku Kogyo in Japan.
Rituximab is currently co-marketed by [[Biogen Idec]] and [[Genentech]] in the U.S., by [[Hoffmann–La Roche]] in Canada and the [[European Union]], and by [[Chugai Pharmaceuticals]] and Zenyaku Kogyo in Japan.

Versio 19. syyskuuta 2012 kello 15.47

Rituximab (MabThera ja Rituxan) on kimeerinen monoklonaalinen vasta-aine lääke potilaille jotka ovat CD20-positiivisia. Rituximab tuhoaa B-soluja ja siksi käytetään hoidettaessa sairauksia joissa esiintyy poikkeavan runsaasti B-soluja, yliaktiivisia B-soluja tai toimintahäiriöisiä B-soluja. Näitä ovat monet Lymfooma, leukemia, elinsiirtojen hylkimis reaktiot ja muutamat autoimmuunisairaudet.


Historiaa

Rituksimabin kehitti IDEC Pharmaceuticals tuotenimellä IDEC-C2B8.[1]

Perustuen kliinisiin tutkimuksiin,[2] rituksimabi sai hyväksynnän USA:n FDA:lta vuonna 1997.[3] Rituksimabia pidetään hyvänä lääkkeenä muiden kanssa hoidettaessa mm. monia B-solu lymfoomia.[4] In 2010 it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma.[5]

Rituximab is currently co-marketed by Biogen Idec and Genentech in the U.S., by Hoffmann–La Roche in Canada and the European Union, and by Chugai Pharmaceuticals and Zenyaku Kogyo in Japan.

Lähteet

  1. ↑ "Why San Diego Has Biotech", Fikes, Bradley J. San Diego Metropolitan, April 1999. Accessed June 20, 2008.
  2. ↑ Maloney DG, Grillo-López AJ, White CA, et al. (September 1997). "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood 90 (6): 2188–95. PMID 9310469. 
  3. ↑ Scott SD (1998). "Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma". Cancer Pract 6 (3): 195–7. doi:10.1046/j.1523-5394.1998.006003195.x. PMID 9652253. 
  4. ↑ Harrison's Principles of Internal Medicine, Longo et al. McGraw Hill Medical 2011 page 931
  5. ↑ "Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy", October 29, 2010. 

Aiheesta muualla

Noudettu kohteesta ”https://fi.wikipedia.org/w/index.php?title=Rituksimabi&oldid=12131115”